Home Services Basic concepts Myths and truths The 555 center Resources Risk management About us Example picks Disclaimer Members login Subscribe

 

 

	My opinion   What traders and investors need to succeed is an edge, a true advantage based on knowledge, but also on intuition, discipline and risk management.

 

 

 

 

	Our edge   Many biotech companies are poised to fail, because their most basic ideas have medical, epidemiological, pharmacological, or toxicological flaws.

About us

Welcome to ShortPicks.com.  I am Varlin, the mind behind the ShortPicks idea.  I love medicine, bioscience and computers, but my true passion is the stock market.  

As many others, I base most of my research on fundamental analysis, for stock valuation, and technical analysis and pattern recognition, for a proper timing.  However, as most investors and traders may have noticed, strong knowledge in these classical tools is not enough to provide consistent gains.  As for stock valuation, markets can stay irrational longer than investors and traders can stay solvent; greed, fear, and, of course, misinformation, will virtually force the vast majority of market participants to buy close to the top and sell close to the bottom, thus losing money.  As for timing, the market is naturally chaotic and nowadays becoming even more unpredictable.  In my opinion, what traders and investors need to succeed is an edge, a true advantage based on knowledge, but also on intuition, discipline and risk management. 

My edge, the one I share with you in this website, includes, but is not limited to, solid knowledge and hands-on experience in

• Medicine and epidemiology

• Biostatistics and data analysis

• Pharmacology and toxicology

• Analytical chemistry

• Computer technology

I combine these "tools", along with classical fundamental and technical analysis, to maximize my finding of pharmaceutical, biotechnological and computer-related companies poised to experience a decrease in value.

Since years ago, when screening for biotech companies in the Nasdaq market, I often asked myself:  "How could this idea ever convince people to invest money on it?".  Many of those companies are now dying penny stocks, after losing more than 90% off their peak market value.  Then, I confirmed I had a strong edge to identify them when their flaws were not too evident and their prices were optimal to capitalize on a potential decline.

The proof is there:  After going public, many "biotech" companies have ended up in a dramatic research failure, financial failure, or both.  And you know what?  Many of them were poised to fail even before their Initial Public Offering (IPO).  There were poised to burn out all the cash they printed, because their most basic ideas, the root of their business, had medical, epidemiological, pharmacological, toxicological and analytical, flaws.  And, because of an inappropriate budget allocation, or the lack of a proper target,  some are still a sure financial failure, even if their research is 100% successful.

I invite you to try ShortPicks.com.  I will provide you my short selling ideas, precise suggestions, and risk management tips; then, you can use that edge to improve your own money-making strategies.

Sincerely,

Please, feel free to contact me at varlin@shortpicks.com.  I also invite you to read an open letter to my visitors: 

A real-life lesson.